# Combination Bortezomib and Rituximab in Patients With Waldenstrom's Macroglobulinemia (WM)

> **NCT00422799** · PHASE2 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 63 (actual)

## Conditions studied

- Waldenstrom's Macroglobulinemia

## Interventions

- **DRUG:** Bortezomib
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT00422799
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08-30
- **Primary completion:** 2015-10-09
- **Final completion:** 2015-10-09
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2020-10-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00422799

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00422799, "Combination Bortezomib and Rituximab in Patients With Waldenstrom's Macroglobulinemia (WM)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00422799. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*